Literature DB >> 19553539

The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.

Adam S Chervin1, Jennifer D Stone, Phillip D Holler, Ailin Bai, Jianzhu Chen, Herman N Eisen, David M Kranz.   

Abstract

TCR interactions with cognate peptide-MHC (pepMHC) ligands are generally low affinity. This feature, together with the requirement for CD8/CD4 participation, has made it difficult to dissect relationships between TCR-binding parameters and T cell activation. Interpretations are further complicated when comparing different pepMHC, because these can vary greatly in stability. To examine the relationships between TCR-binding properties and T cell responses, in this study we characterized the interactions and activities mediated by a panel of TCRs that differed widely in their binding to the same pepMHC. Monovalent binding of soluble TCR was characterized by surface plasmon resonance, and T cell hybridomas that expressed these TCR, with or without CD8 coexpression, were tested for their binding of monomeric and oligomeric forms of the pepMHC and for subsequent responses (IL-2 release). The binding threshold for eliciting this response in the absence of CD8 (K(D) = 600 nM) exhibited a relatively sharp cutoff between full activity and no activity, consistent with a switchlike response to pepMHC on APCs. However, when the pepMHC was immobilized (plate bound), T cells with the lowest affinity TCRs (e.g., K(D) = 30 microM) responded, even in the absence of CD8, indicating that these TCR are signaling competent. Surprisingly, even cells that expressed high-affinity (K(D) = 16 nM) TCRs along with CD8 were unresponsive to oligomers in solution. The findings suggest that to drive downstream T cell responses, pepMHC must be presented in a form that supports formation of appropriate supramolecular clusters.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553539      PMCID: PMC2841305          DOI: 10.4049/jimmunol.0900054

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Engineering and characterization of a stabilized alpha1/alpha2 module of the class I major histocompatibility complex product Ld.

Authors:  Lindsay L Jones; Susan E Brophy; Alexander J Bankovich; Leremy A Colf; Nicole A Hanick; K Christopher Garcia; David M Kranz
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

3.  Full activation of the T cell receptor requires both clustering and conformational changes at CD3.

Authors:  Susana Minguet; Mahima Swamy; Balbino Alarcón; Immanuel F Luescher; Wolfgang W A Schamel
Journal:  Immunity       Date:  2006-12-21       Impact factor: 31.745

4.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

5.  Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling.

Authors:  Mark A Daniels; Emma Teixeiro; Jason Gill; Barbara Hausmann; Dominique Roubaty; Kaisa Holmberg; Guy Werlen; Georg A Holländer; Nicholas R J Gascoigne; Ed Palmer
Journal:  Nature       Date:  2006-11-01       Impact factor: 49.962

Review 6.  How TCRs bind MHCs, peptides, and coreceptors.

Authors:  Markus G Rudolph; Robyn L Stanfield; Ian A Wilson
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

7.  Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality.

Authors:  Pia P Yachi; Jeanette Ampudia; Tomasz Zal; Nicholas R J Gascoigne
Journal:  Immunity       Date:  2006-07-27       Impact factor: 31.745

8.  Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Authors:  Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille J Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

9.  Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response.

Authors:  Nadia Anikeeva; Tatiana Lebedeva; Aaron R Clapp; Ellen R Goldman; Michael L Dustin; Hedi Mattoussi; Yuri Sykulev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

10.  Molecular flexibility can influence the stimulatory ability of receptor-ligand interactions at cell-cell junctions.

Authors:  Shuyan Qi; Michelle Krogsgaard; Mark M Davis; Arup K Chakraborty
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

View more
  47 in total

1.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

2.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

3.  T Cell Receptor Engineering and Analysis Using the Yeast Display Platform.

Authors:  Sheena N Smith; Daniel T Harris; David M Kranz
Journal:  Methods Mol Biol       Date:  2015

4.  Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides.

Authors:  Diego J Farfán-Arribas; Lawrence J Stern; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

5.  Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex.

Authors:  Daniel T Harris; Ningyan Wang; Timothy P Riley; Scott D Anderson; Nishant K Singh; Erik Procko; Brian M Baker; David M Kranz
Journal:  J Biol Chem       Date:  2016-09-28       Impact factor: 5.157

6.  High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.

Authors:  Dylan T Blaha; Scott D Anderson; Daniel M Yoakum; Marlies V Hager; Yuanyuan Zha; Thomas F Gajewski; David M Kranz
Journal:  Cancer Immunol Res       Date:  2018-11-13       Impact factor: 11.151

7.  Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.

Authors:  Milos Aleksic; Omer Dushek; Hao Zhang; Eugene Shenderov; Ji-Li Chen; Vincenzo Cerundolo; Daniel Coombs; P Anton van der Merwe
Journal:  Immunity       Date:  2010-02-04       Impact factor: 31.745

8.  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Authors:  Thomas M Schmitt; David H Aggen; Ingunn M Stromnes; Michelle L Dossett; Sarah A Richman; David M Kranz; Philip D Greenberg
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

9.  Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Authors:  Jennifer D Stone; Adam S Chervin; Hans Schreiber; David M Kranz
Journal:  Biotechnol Prog       Date:  2012-10-18

10.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Authors:  Jennifer D Stone; Daniel T Harris; Carolina M Soto; Adam S Chervin; David H Aggen; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2014-08-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.